# Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

> **NCT00328172** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 302 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** BI 1356 dose 3 once daily
- **DRUG:** BI 1356 dose 2 once daily
- **DRUG:** BI 1356 dose 1 once daily
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00328172
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2014-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328172, "Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00328172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*